Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 14 | 2024 | 11039 | 0.620 |
Why?
|
Retinoblastoma-Like Protein p107 | 1 | 2017 | 74 | 0.590 |
Why?
|
Neuroendocrine Tumors | 4 | 2023 | 594 | 0.520 |
Why?
|
Resorcinols | 1 | 2014 | 38 | 0.490 |
Why?
|
Androgen Antagonists | 4 | 2024 | 1350 | 0.450 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2022 | 325 | 0.440 |
Why?
|
Isoxazoles | 1 | 2014 | 216 | 0.440 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2014 | 434 | 0.400 |
Why?
|
Taxoids | 1 | 2014 | 665 | 0.380 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2017 | 2948 | 0.350 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2021 | 5163 | 0.320 |
Why?
|
Adenocarcinoma | 3 | 2021 | 6347 | 0.280 |
Why?
|
Receptors, Androgen | 4 | 2021 | 1057 | 0.270 |
Why?
|
Cell Line, Tumor | 16 | 2023 | 16665 | 0.270 |
Why?
|
SOXB1 Transcription Factors | 2 | 2017 | 284 | 0.260 |
Why?
|
Carcinoma, Renal Cell | 5 | 2019 | 3123 | 0.250 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 2023 | 76 | 0.230 |
Why?
|
Epigenesis, Genetic | 4 | 2020 | 3639 | 0.230 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13655 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2021 | 8425 | 0.220 |
Why?
|
PTEN Phosphohydrolase | 3 | 2023 | 1144 | 0.210 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2022 | 77 | 0.200 |
Why?
|
Retinoblastoma Binding Proteins | 2 | 2023 | 97 | 0.200 |
Why?
|
Neuroendocrine Cells | 1 | 2021 | 61 | 0.190 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2021 | 170 | 0.190 |
Why?
|
Glutamates | 1 | 2022 | 398 | 0.190 |
Why?
|
Molecular Probes | 1 | 2022 | 316 | 0.180 |
Why?
|
Tumor Microenvironment | 4 | 2023 | 3564 | 0.180 |
Why?
|
DNA Topoisomerases, Type II | 2 | 2017 | 121 | 0.180 |
Why?
|
Mice, SCID | 5 | 2019 | 2715 | 0.180 |
Why?
|
Urea | 1 | 2022 | 449 | 0.170 |
Why?
|
Indoles | 4 | 2015 | 1834 | 0.170 |
Why?
|
Kidney Neoplasms | 4 | 2018 | 4229 | 0.170 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2021 | 504 | 0.160 |
Why?
|
Angiopoietin-2 | 1 | 2019 | 170 | 0.160 |
Why?
|
Pyrroles | 2 | 2014 | 1143 | 0.160 |
Why?
|
Antigens, Surface | 1 | 2022 | 1663 | 0.150 |
Why?
|
Lysine | 1 | 2022 | 1008 | 0.150 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2018 | 2107 | 0.140 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2018 | 563 | 0.140 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 314 | 0.140 |
Why?
|
Histone Deacetylase 1 | 1 | 2016 | 137 | 0.130 |
Why?
|
Phenylthiohydantoin | 1 | 2017 | 192 | 0.130 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7721 | 0.120 |
Why?
|
Oncogene Protein v-akt | 1 | 2013 | 135 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1637 | 0.120 |
Why?
|
DNA Methylation | 3 | 2024 | 4282 | 0.110 |
Why?
|
Indazoles | 1 | 2014 | 287 | 0.110 |
Why?
|
Male | 26 | 2024 | 349538 | 0.110 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4839 | 0.110 |
Why?
|
Mice | 12 | 2023 | 81045 | 0.110 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2023 | 1860 | 0.100 |
Why?
|
Receptor, erbB-2 | 1 | 2021 | 2410 | 0.100 |
Why?
|
Histone Deacetylases | 1 | 2016 | 729 | 0.100 |
Why?
|
Neoplasms, Experimental | 1 | 2017 | 1274 | 0.100 |
Why?
|
Imidazoles | 2 | 2014 | 1205 | 0.100 |
Why?
|
Cell Lineage | 2 | 2017 | 2504 | 0.100 |
Why?
|
Disease Progression | 5 | 2022 | 13256 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11001 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2014 | 578 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2018 | 3557 | 0.090 |
Why?
|
Animals | 15 | 2023 | 168561 | 0.090 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5851 | 0.080 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2014 | 1333 | 0.080 |
Why?
|
Medical Oncology | 1 | 2019 | 2235 | 0.080 |
Why?
|
Cell Proliferation | 4 | 2021 | 10472 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3691 | 0.080 |
Why?
|
Transplantation, Heterologous | 1 | 2014 | 2382 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5522 | 0.070 |
Why?
|
Humans | 26 | 2024 | 742088 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 11472 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 2 | 2022 | 2505 | 0.060 |
Why?
|
Prostate | 2 | 2023 | 1764 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2022 | 18006 | 0.060 |
Why?
|
Pyrazoles | 1 | 2014 | 1970 | 0.060 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6483 | 0.060 |
Why?
|
Prostate-Specific Antigen | 2 | 2024 | 2458 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2014 | 3502 | 0.060 |
Why?
|
A Kinase Anchor Proteins | 1 | 2023 | 51 | 0.060 |
Why?
|
Pyridines | 1 | 2014 | 2818 | 0.050 |
Why?
|
Receptors, Kainic Acid | 1 | 2022 | 88 | 0.050 |
Why?
|
Binding Sites | 2 | 2022 | 6115 | 0.050 |
Why?
|
Cell Cycle Proteins | 2 | 2023 | 3444 | 0.050 |
Why?
|
Molecular Conformation | 1 | 2022 | 563 | 0.050 |
Why?
|
Biopsy | 2 | 2024 | 6756 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2022 | 11363 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 2938 | 0.040 |
Why?
|
Mutation | 3 | 2021 | 29717 | 0.040 |
Why?
|
Carbazoles | 1 | 2021 | 226 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2023 | 1727 | 0.040 |
Why?
|
Cadherins | 1 | 2023 | 906 | 0.040 |
Why?
|
Integrins | 1 | 2022 | 845 | 0.040 |
Why?
|
Apoptosis | 1 | 2014 | 9715 | 0.040 |
Why?
|
Protein Binding | 2 | 2022 | 9387 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2015 | 9639 | 0.040 |
Why?
|
Androgens | 1 | 2024 | 1271 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6534 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2022 | 3133 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 713 | 0.030 |
Why?
|
Epigenomics | 1 | 2021 | 902 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2021 | 1782 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6891 | 0.030 |
Why?
|
Prostatectomy | 1 | 2024 | 1871 | 0.030 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2015 | 87 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 2502 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2022 | 831 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2016 | 553 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2022 | 1915 | 0.030 |
Why?
|
Cell Membrane | 1 | 2023 | 3744 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2016 | 892 | 0.030 |
Why?
|
Etoposide | 1 | 2015 | 637 | 0.030 |
Why?
|
Neuroblastoma | 1 | 2021 | 1225 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2721 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2021 | 1376 | 0.030 |
Why?
|
Piperidines | 1 | 2021 | 1602 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 9410 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2024 | 3020 | 0.030 |
Why?
|
RNA Interference | 1 | 2021 | 2890 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6313 | 0.030 |
Why?
|
Gene Silencing | 1 | 2018 | 1538 | 0.030 |
Why?
|
Nitriles | 1 | 2017 | 952 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 1655 | 0.020 |
Why?
|
Models, Molecular | 1 | 2022 | 5454 | 0.020 |
Why?
|
Benzamides | 1 | 2017 | 1378 | 0.020 |
Why?
|
Signal Transduction | 3 | 2021 | 23387 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2940 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2013 | 495 | 0.020 |
Why?
|
Microvessels | 1 | 2014 | 544 | 0.020 |
Why?
|
Drug Synergism | 1 | 2014 | 1791 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2018 | 1581 | 0.020 |
Why?
|
Pyridones | 1 | 2015 | 712 | 0.020 |
Why?
|
Random Allocation | 1 | 2013 | 2425 | 0.020 |
Why?
|
Quinolines | 1 | 2013 | 719 | 0.020 |
Why?
|
Gene Expression | 1 | 2022 | 7790 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5180 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 789 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3612 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29010 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2020 | 2522 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 53187 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 21821 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4438 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6259 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2015 | 1983 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10248 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5975 | 0.020 |
Why?
|
Up-Regulation | 1 | 2015 | 4211 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12773 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9185 | 0.020 |
Why?
|
Computational Biology | 1 | 2017 | 3518 | 0.020 |
Why?
|
Cell Movement | 1 | 2016 | 5212 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12164 | 0.010 |
Why?
|
DNA Damage | 1 | 2013 | 2423 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2016 | 9735 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3070 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2024 | 62966 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14554 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10943 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2015 | 13029 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15056 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12220 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39004 | 0.010 |
Why?
|
Aged | 2 | 2020 | 162944 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 40450 | 0.010 |
Why?
|
Middle Aged | 2 | 2020 | 213127 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 57683 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40054 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2020 | 77098 | 0.010 |
Why?
|
Female | 2 | 2020 | 379592 | 0.010 |
Why?
|
Adult | 1 | 2018 | 213712 | 0.000 |
Why?
|
Concepts
(170)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(32)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_